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Background: Diabetes is a long-term condition that can be treated and controlled but
do not yet have a cure; it could be induced by inflammation and the goal of managing
it is to prevent additional co-morbidities and reduce glycemic fluctuations. There is a
need to examine inflammatory activities in diabetes-related angiopathies and explore
interventions that could reduce the risk for future outcome or ameliorate its effects to
provide insights for improved care and management strategies.
Method: The study was conducted in Embase (1946–2020), Ovid Medline (1950–2020),
and PubMed databases (1960–2020) using the PICO framework. Primary studies
(randomized controlled trials) on type 2 diabetes mellitus and inflammatory activities in
diabetes-related angiopathies were included. Terms for the reviewwere retrieved from the
Cochrane library and from PROSPERO using its MeSH thesaurus qualifiers. Nine articles
out of 454 total hits met the eligibility criteria. The quality assessment for the selected
study was done using the Center for Evidence-Based Medicine Critical Appraisal Sheet.
Results: Data analysis showed that elevated CRP, TNF-α, and IL-6 were the
most commonly found inflammatory indicator in diabetes-related angiopathies, while
increased IL-10 and soluble RAGE was an indicator for better outcome. Use of drugs
such as salsalate, pioglitazone, simvastatin, and fenofibrate but not glimepiride or
benfotiamine reported a significant decrease in inflammatory events. Regular exercise
and consumption of dietary supplements such as ginger, hesperidin which have
anti-inflammatory properties, and those containing prebiotic fibers (e.g., raspberries)
revealed a consistent significant (p < 0.05) reduction in inflammatory activities.
Conclusion: Inflammatory activities are implicated in diabetes-related angiopathies;
regular exercise, the intake of healthy dietary supplements, and medications with
anti-inflammatory properties could result in improved protective risk outcome for diabetes
patients by suppressing inflammatory activities and elevating anti-inflammatory events.
Keywords: diabetic angiopathy, inflammation, commorbidity, intervention study, diabetes miletus
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BACKGROUND
Diabetes is a chronic condition with rising global prevalence
that is associated with multimorbidity (1). It is linked with
metabolic abnormalities such as increased oxidative stress, free
radicals, accumulated free fatty acids in the blood, and the onset
of inflammatory changes (2). There are currently no cures for
diabetes and its signs and severity differ among people of different
ethnic groups (2). The economic cost of treating diabetes
increases with increasing age and even more so for clinically
managing the disease and its associated comorbidities (3).
The clinical treatment goal in managing people with diabetes
is to prevent the onset of associated co-morbidities by relieving
symptoms, and controlling hyperglycemia and hypoglycemic
episodes upon diagnosis (2). According to Reutrakul and
Mokhlesi (4) people living with type 2 diabetes mellitus (T2DM)
constitute about 90–95% of all people living with diabetes,
and they often present several associations with hypertension,
cardiovascular diseases, nephropathy, retinopathy, depression,
inflammatory and neurodegenerative diseases, and so on, most
of which are recognized when co-morbidities becomes evident
(5). About 97.5% of people with T2DM have at least one co-
morbid condition while about 88.5% have two or more additional
disorders (6).
Although inflammation has been associated with diabetes
(2), the key question remains on finding supporting strategies
that prevent worsening outcome. Inflammation is a pathological
process caused by diverse cytologic and chemical reactions
(7). The hallmarks of inflammation are dysfunction and
injury to tissues usually manifested by loss of function,
heat, pain, and swelling (7). Damage to small blood vessels
(diabetic microangiopathy) and to the larger vessels (diabetic
macroangiopathy) generally referred to as diabetic angiopathy
is the major vascular complication of diabetes (8). Diabetic
microangiopathy includes diabetic retinopathy, nephropathy,
and neuropathy, whereas complications from macroangiopathy
include cardiovascular events such as heart attacks, strokes, and
insufficient blood flow (8). Evidence from large randomized
controlled trials (RCTs) have suggested that optimal metabolic
control in T2DM could delay the onset of both diabetic micro
and macroangiopathy (8). Moreover, changes in metabolic status
such as changes in the status of cytokines in adipose tissues could
increasingly alter insulin action (9). The accrual of circulating
pro-inflammatory cytokines and reactive oxygen species (ROS)
in prediabetes patients have been reported to disrupt intestinal
barriers and compromise tight junctions between cells allowing
for deleterious compounds to be increasingly absorbed (10).
Abbreviations: AIM-HIGH, Atherothrombosis Intervention in Metabolic
Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes
Trial; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C reactive protein; TNF-α,
umor necrosis factor-alpha; IL, interleukin; sRAGE, soluble receptor for advanced
glycation end-products; sAA, serum amyloid A; ICAM-1, intercellular adhesion
molecule 1; MPC-1, monocyte chemoattractant protein-1; WBC, white blood cell;
TAC, total antioxidant capacity; MPO, myeloperoxidase; T2DM, type 2 diabetes
mellitus; T1DM, type 1 diabetes mellitus; TINSAL-T2D, Targeting Inflammation
Using Salsalate for Type 2 Diabetes.
Pro-inflammatory cytokine production activates
myeloperoxidase enzymes and NADPH oxidase (NOX)
involved in amino acid oxidation to produce advanced glycation
end-product (AGE) precursors (11). Like pro-inflammatory
cytokines, AGE is a biomarker for vascular complications (12);
its production within the body is accelerated by oxidative stress,
dyslipidemia, and hyperglycemic conditions associated with
diabetes patients (13), and is particularly elevated in people who
also have impaired renal function due to decreased urinary AGE
excretion (14). The ability of the receptor for advanced glycation
end-products (RAGE) to interact and bind with AGEs is thought
to promote atherosclerosis, endothelial dysfunction, and has
an inflammatory effect in diabetes complications by inducing
lipid abnormalities, oxidative stress, and macrophage uptake via
upregulation of inflammatory cytokines such as IL-1, IL-6, and
TNF (15–17).
The objective of the study was to systematically review
literature to investigate inflammatory activities in diabetes-
related angiopathies and to explore beneficial interventions, as
the evidence to support strategies to successfully cope with
the chronic illness of T2DM is patchy, and the possibility for
worsening condition or reversal substantial (18). The overarching
aim of the study was to identify
1. Inflammatory activities in T2DM-related angiopathies and
2. Beneficial interventions for reducing the risk of
inflammatory activities.
The remaining sessions of this study will discuss the
methodology, search strategy, and quality assessment of the
systematic review. Next, inflammatory activities and T2DM-
related angiopathies will be overviewed in relation with
findings from the selected studies. A narrative synthesis of the
effect of interventions on measures of inflammation will be
included. The study will conclude by summarizing the findings




This study reviewed only RCTs (19). Since the outcome of interest
was to investigate inflammatory activities in diabetes-related
angiopathies and explore beneficial interventions, articles from
RCTs reporting inflammatory activities in people with diabetic
angiopathies after an intervention or in comparison with an
experimental group were of interest. The study was registered in
PROSPERO (CRD42020204001).
Inclusion and Exclusion Criteria
Only articles from peer-reviewed journals published in English
with a focus on human subjects (18+ years) and from any
country were included. The timeline of study in the selected
RCTs was at least 14 days. Included studies reported the outcome
of an intervention on inflammatory markers, namely, drugs,
dietary supplement, aerobic exercise, as well as blood glucose
levels and risk for diabetic angiopathy. The significant differences
in measures of inflammation after the intervention in each
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TABLE 1 | Inclusion/exclusion criteria.
Inclusion Exclusion Rationale
Population Type 2 diabetes
patients
People who do not have diabetes or
other types of diabetes will not be
included
To review inflammatory activities in
T2DM-related angiopathies
Exposure Inflammation Inflammation not linked with diabetes To focus on inflammatory activities as
well as beneficial interventions
Comparison Healthy individuals
Outcome Diabetic angiopathies Other co-morbidities that are not
diabetic angiopathy
To investigate induced-risk for
inflammation and strategies for
improved protection
TABLE 2 | Search items.
Diabetes (type 2)
(step 1)
Co-morbidity (step 2) Exposure
(step 3)
Terms
“Type 2 diabetes” OR






















































Combined with OR Combined with OR Combined
with OR
RCT were reported. Animal studies were excluded. The PICO
framework used to define the eligibility criteria is seen below:




Only RCTs on type 2 diabetes reporting inflammatory activities in
diabetes-related angiopathies and beneficial interventions were
eligible (see Table 1). Studies involving people who do not have
diabetes or other types of diabetes were excluded. The search
items can be seen in Table 2.
Search Strategy
The review was conducted in Ovid Medline, Embase, and
PubMed databases. Ovid Medline is a large database of
healthcare, medicine, and scientific disciplines. PubMed is a
biomedical and genomic database accessed from the National
Center for Biotechnology Information (NCBI) platform, whereas
Embase is a widely used biomedical and pharmacological
bibliographic database hosted on Elsevier. Keywords for the
population, exposure, and outcome were used to search
each database. Terms for the population “type 2 diabetes
patients” and outcome “diabetic angiopathies” were retrieved
from the Cochrane library (20), whereas terms for the
exposure “inflammation” were identified using PROSPERO
MeSH thesaurus qualifiers (7). The terms can be seen in the
database search history (Appendix 1: PubMedQueries; Appendix
2: Ovid Medline Queries; Appendix 3: Embase Query).
The key categories searched were diabetes (type 2),
inflammation, and diabetic angiopathies. Synonyms for
each key category generated were individually searched and
then collectively combined with the “OR” logical operator. An
intersection between the three key categories searched was done
using the “AND” operator as shown in Table 2. The screening
process from the three databases yielded 454 total hits and is
presented in the PRISMAflow diagram in Figure 1. One hundred
and ninety-one duplicates were removed after initial screening
by titles and abstracts. Two-hundred and five articles were not
included because they did not meet the eligibility criteria. Out
of the 58 articles left, 49 were excluded for not fully meeting the
selection criteria as they either only highlighted protocols or
were about inflammation linked with other disorders. Nine RCTs
met the inclusion criteria and were included in the narrative
synthesis and quality appraisal of the findings.
Data Extraction and Quality Assessment
Data from the nine selected studies were extracted under
these headings: name of author(s), year of publication, study
design, co-morbidity type, inflammatory associations, methods,
and intervention as seen in Table 3. The quality assessment of
the selected studies was done using the Center for Evidence-
Based Medicine Critical Appraisal Sheet (21). Data about
the participants, interventions used for the RCTs, objectivity
of the blind study, if the groups were similar and treated
equally at the start of the trial, and validity of the outcome
of treatment were examined using the CEBM appraisal sheet.
The validity of the outcome of treatment for each study was
rated “high,” “moderate,” or “low” based on the quality (22).
The criteria for rating were lack of blinding, selective outcome
reporting, and incomplete accounting of outcome events based
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FIGURE 1 | PRISMA flow diagram.
on the GRADES guidelines by Guyatt et al. (22). Studies
that did not meet all three criteria were considered as “high
quality,” those that met only one were considered “moderate
quality” while those that met two or more were considered
“low quality.” Inflammatory mechanisms from the RCTs were
analyzed and used in explaining the activities of inflammation in
diabetes-related angiopathies.
RESULTS
The result of the database search is presented in Table 4. From
the selected studies in Table 5, the highlighted inflammatory
activities were high-sensitivity C reactive protein (hs-CRP),
myeloperoxidase (MPO), serum amyloid-A (sAA), tumor
necrosis factor-alpha (TNF-α), interleukins (IL-1, IL-2, IL-6,
IL-18, IL-10), soluble receptor for advanced glycation end-
products (sRAGE), intercellular adhesion molecule-1 (ICAM-
1), monocyte chemoattractant protein-1 (MPC-1), white blood
cells (WBC), and total anti-oxidant capacity (TAC) (23). Hs-
CRP was the most common inflammatory biomarker as it was
measured by seven of the nine selected studies. This was closely
followed by TNF-α (five times) and IL-6 (four times). TNF-
α, IL-1β, IL-6, MCP-1, IL-2, and interferon-γ are some of the
monocyte- and lymphocyte-derived pro-inflammatory cytokines
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Alkhalaf et al. (23) Baseline characteristics
shows equal treatment
Participants were
accounted for and the
lack of follow-up was
explained. However,









accounting of outcome events
and selective outcome reporting
Limitation: Participants also had
other medications such as
angiotensin receptor blockers
(ARBs), ACE inhibitors
Choi et al. (24) Baseline characteristics
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by the participants is a
limitation
Yes Significant: Hesperidin was
found to have anti-inflammatory
effects in T2DM
Moderate quality: Incomplete
accounting of outcome events
Limitation: Unreported or poor
dietary compliance of hesperidin
supplement by the participants










No Significant: Daily raspberry
consumption lowered IL-6 and
hs-TNF-α (p < 0.05)
Not significant: CRP levels
Moderate quality:
No blinding
Limitation: Short duration of
study
Barzilay et al. (27) Participants who
received salsalate had
a higher heart rate
(74.16 10.8 vs. 71.06
















were older adults less
likely to be non-whites









- Early AGE was reduced, late








was not exactly known. Most
participants in the
salsalate-treated group also took








were more women (34)
than men (26)
No Significant: There was a







- The participants had no history
of cardiovascular complications
- The intensity of exercise for the
experimental group was
unclear




were more males (108)
than females (82)
Yes Significant: Found significant
decrease (p = 0.001) in all of
TNF, IL-1, IL-2, IL-6, MCP-1, and
CRP inflammatory markers after
a combined treatment with
simvastatin and fenofibrate, but a
weak correlation (r = 0.20) with
single fenofibrate administration
High quality. Limitation: While
there was agreement on
combined simvastatin and
fenofibrate administration, there
were mixed results with the
ACCORD trial on monotherapy
(Continued)
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supplementation led to a change
in ADMA after intervention, but a





Limitation: ADMA and serum
ICAM-1 differences between the








toward males (39) than
females (13)
Yes Significant: HDL increased, while
hs-CRP levels decreased after
pioglitazone (p < 0.01)
treatment. Glimepiride increased
hs-CRP (p < 0.05)
High quality. Limitation: Small
participant size, participants
were on other drugs, short
duration of studies but findings
concurred with few
similar studies
TABLE 4 | Database search results.









Result of steps 1, 2,
and 3 combined with
‘AND’ operator
Embase 123,834 9,687 1,211,662 131
Ovid Medline 130,433 12,120 538,190 104
PubMed 179,274 14,951 567,008 219
Total 433,541 36,758 2,316,860 454
(29). These cytokines including CRP are markers of chronic
low-grade systemic inflammation and a prognostic indicator of
vascular complications and increased cardiovascular risk (29).
While IL-10 is an anti-inflammatory cytokine, IL-18 is a pro-
inflammatory cytokine. The IL-18/IL-10 ratio represents the
balance that foretells the incidence of coronary complications
(32–34). The elevation of IL-18 promotes atherosclerosis by
interferon-γ release which are balanced by IL-10 cytokines (32,
35). Thus, disequilibrium of IL-18/IL-10 ratio may promote
atherosclerotic process.
Overview of the Findings
An overview of the findings from the nine selected studies
(Table 5) shows that the interventions could be explained
and grouped into three main categories: exercise, diet, and
medication. Two studies (24, 28) investigated the effects of
aerobic exercise on markers of inflammation (hs-CRP, sRAGE,
IL-6, IL-10, IL-18) in T2DM participants with cardiovascular
or cardiometabolic risk. Three studies (25, 26, 30) examined
the effect of dietary supplements, while four studies (23, 27,
29, 31) investigated the use of medication as an intervention.
A further overview and appraisal of each study under the
appropriate category (exercise, diet, medication) is explored in
the following section.
Effect of Aerobic Exercise on Measures of
Inflammation in People With T2DM
To understand inflammatory activities in T2DM, Choi et al.
(24) explored the effects of exercise on inflammatory markers
and soluble receptor for AGEs on 75 patients with T2DM
for 12 weeks and found that, apart from the physical benefits
of exercise that was observed such as a reduction in waist
circumference, and loss of weight and body fat percentage
leading to a reduction in risk factors for atherosclerosis and
cardiometabolic diseases (e.g., decrease in blood pressure, free
fatty acids, oxidative stress), there was a significant decrease in
the levels of hs-CRP and an increase in soluble receptor for
AGEs in the exercise group but not in the control group, which
suggests that aerobic exercise improved systemic inflammatory
state in T2DM. While the level of moderate intensity of the
aerobic exercise may not be exactly quantified, the study found an
independent association (R2 = 0.244) of age, glucose, cholesterol
levels, and triglyceride with soluble receptor for AGEs (24).
Although this is a weak association, it implies that aerobic
exercise had a positive influence on glucose, cholesterol, and
triglyceride levels. Similarly, Kadoglou et al. (28) found that
aerobic exercise undertaken four times a week lessens the
effect of inflammatory activities and improved anti-inflammatory
markers after 6 months. The study reported improvement
in glucose control, insulin resistance, and anti-inflammatory
protection via increased IL-10 (4.14 ± 5.65 vs. −0.23 ± 4.73
pg/ml), and suppression of IL-18, and IL-18/IL-10 ratio (p >
0.05) in 60 overweight patients with T2DM who do not have
vascular complications (28). Although TNF-α levels (p = 0.77)
remained constant, hs-CRPwas significantly decreased (p= 0.04)
and was independent of significant alteration in IL-18 as the
participants were reported to be on antidiabetic drugs (28). Also,
systolic blood pressure was considerably improved (p < 0.05),
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inflammatory markers
IL-6 (p = 0.001) and
hs-CRP increased (p <
0.000), TAC (p <
0.000) decreased
Schell et al. (26) Randomized
crossover
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Female: 20 Age: 54 ±
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while diastolic blood pressure decreased and IL-10 was elevated
after the exercise program.
Exercise has been reported in previous studies to ameliorate
cellular apoptosis, atherosclerotic plaque, tissue factor
expression, and nuclear factor-κB activation (36–38). While
these findings are revealing and an enhancement of IL-10
levels were reported in T2DM participants by Kadoglou et al.
(28) after exercise training, the participants had no history of
cardiovascular complications which limits the study conclusions
for aerobic exercise as an intervention for protective risk
outcome in diabetic angiopathy. Taken together, the study by
Choi et al. (24) and Kadoglou et al. (28) reported a reduction
in hs-CRP after an aerobic exercise; Choi et al. (24) found a
statistically significant difference (p < 0.013) in the levels of hs-
CRP measured at the start and end of the study, while Kadoglou
et al. (28) reported a 39.6% reduction in hs-CRP (p < 0.04) at
the end of the aerobic exercise. Choi et al. (24) also reported
a statistically significant difference (p < 0.05) in the levels of
IL-6 for the exercise group compared with the control. While
participants in the study by Choi et al. (24) had both vascular
and cardiometabolic risk, those in Kadoglou et al. (28) were
reported to have only cardiovascular risk. The anti-inflammatory
effects of exercise seemed to result in greater significant effect
size as it correlated to decreased HbA1c and blood pressure,
and was negatively correlated with increased soluble receptor
for AGEs which suggest that aerobic exercise improved systemic
inflammatory state in T2DM.
Effect of Dietary Supplement on Measures
of Inflammation in People With T2DM
Dietary supplements such as ginger powder, dietary raspberries,
and hesperidin were the intervention used by Zarezadeh et al.
(30), Schell et al. (26), and Homayouni et al. (25), respectively, to
investigate intervention effectiveness on inflammatory activities
linked with vascular complications. Schell et al. (26) and
Homayouni et al. (25) found a significant reduction (p < 0.05)
in levels of IL-6, TNF-α, and hs-TNF, while Zarezadeh et al.
(30) reported that ginger supplement decreased serum ICAM-
1 marginally, serum ICAM-1 has previously been associated
with the pathogenesis of cardiovascular disease in T2DM. Schell
et al. (26) did not find a significant difference in CRP after red
raspberries were consumed, but reported that daily raspberry
consumption for a period of 4 weeks showed a consistently
significant lowering effect (p < 0.05) on IL-6 and high-sensitivity
TNF-α (hs-TNF-α) at 4 h postprandial after meal.
Furthermore, hesperidin was suggested to have anti-
inflammatory effects in T2DM as there was a significant
difference (p < 0.05) in TNF-α, hs-CRP, and IL-6 inflammatory
markers between the control and experimental groups of
the RCT that investigated the consumption of hesperidin
supplement and its effect on blood pressure and inflammatory
activities on 64 T2DM patients (25). A statistically significant
(p = 0.001) decrease in levels of TNF-α and IL-6 (p = 0.034)
markers of inflammation, respectively, was reported, but no
difference in the mean hs-CRP, rather an increased serum total
antioxidant capacity (TAC) at the end in comparison with
baseline values was reported. In addition, the percent change of
TNF-α, IL-6, and hs-CRP levels were significantly reduced in the
treated group compared with the control (p < 0.05), indicating
that hesperidin has anti-inflammatory effects in T2DM (25).
Although the study reported repeated assessment of dietary
components and showed that hesperidin may improve TAC and
reduce inflammation in patients with T2DM, unreported or poor
dietary compliance of hesperidin supplement by the participants,
the inability to measure antioxidant enzymes and serum nitric
oxide (NO) level, and lack of intention-to-treat analysis could
have limited the study findings (25).
The long- and short-term hesperidin administration have
been reported to have anti-hypertensive effects and to stimulate
NO production via phosphorylation of enzymes that mediate its
output in vascular endothelial cells (39, 40). Hesperidin probably
controls vascular tone by increasing vasorelaxing factors like NO
or other tone modulating products such as NADPH oxidase (41,
42). It is believed that the onset of ROS disrupts NO production
and leads to an increase in prostaglandin-like compounds that
are suggested to have proinflammatory actions (25). The anti-
inflammatory and antioxidant benefits of hesperidin are strongly
correlated with hypertension and oxidative stress; (43) and it
has been reported that hesperidin represses ROS-generating
enzymes (43–45). It is important that ROS are repressed because
inflammation in diabetic condition is induced by elevated ROS
(25) which promotes the pathogenesis of cardiovascular disease
in people with T2DM, and this can be measured through changes
in ICAM-1 (inter-cellular adhesion molecule-1) and ADMA
(asymmetric dimethylarginine) biomarkers (30).
A significant difference in ADMA serum levels (p= 0.002) and
a marginal change in serum ICAM-1 (p = 0.097) were reported
in the ginger supplementation group by Zarezadeh et al. (30) in
the study to determine the effect of ginger supplementation on
ICAM-1 serum levels and ADMA in 45 patients with T2DM after
10 weeks. In the same study, another intervention group received
wheat flour, but the ADMA and serum ICAM-1 differences
between the groups were not statistically significant, giving slight
credence to ginger as a possible intervention. The study by
Zarezadeh et al. (30) was conducted in a University hospital in
Iran and did not include information on the participant’s gender
(30). Similarly, the study by Homayouni et al. (25) which was also
conducted in a University hospital in Iran had no information on
the participant’s gender, but that by Schell et al. (26) carried out
in a clinical assessment unit in the USA had gender information
and the selected participants consisted of more males (25) than
females (5).
Effect of Medication on Measures of Inflammation in
People With T2DM
A handful of studies have investigated the anti-inflammatory
effect of medication on measures of inflammation. Alkhalaf
et al. (23) studied the outcome of benfotiamine intervention
in atherosclerotic plaque inflammation. The investigation
of benfotiamine and its effect on markers of low-grade
inflammation in 39 T2DM patients with nephropathy who
had high-normal urinary albumin excretion(UAE) and UAE
in the microalbuminuric range (15–300 mg/24 h) found no
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significant change in hs-CRP, MPO, and sAA compared with
the control group after 12 weeks (23). Markers of endothelial
dysfunction and AGE yielded insignificant results, suggesting
that inflammation-induced vascular complications in T2DM are
unaffected by benfotiamine (23), although the patients were
found to have had other medications such as angiotensin
receptor blockers (ARBs) and ACE inhibitors which might
have introduced confounding. While Alkhalaf et al. (23) found
no significant difference in hs-CRP, sAA, and MPO between
the benfotiamine or placebo-treated groups, Mizoguchi et al.
(31) reported that hs-CRP levels decreased after pioglitazone
(p < 0.01) treatment but increased marginally by glimepiride
(p < 0.05), and the increasing hs-CRP levels were associated
with atherosclerotic plaque inflammation. However, the small
number of participants on pioglitazone (31 patients), some who
were on other medications such as statins, aspirin, and renin–
angiotensin system inhibitors, could potentially have introduced
confounding variables that may interact with the efficacy of the
intervention via drug–drug interaction (46). The short duration
of the study and the fact that only atherothrombotic stroke was
of interest is a limitation of the generalizability of the study with
regards to diabetic angiopathies (31).
In a similar experiment to investigate the outcome
of pioglitazone treatment, Mizoguchi et al. (31) found
increased high-density lipoprotein (HDL) upon pioglitazone
administration, though when compared with glimepiride,
a stepwise multiple regression analysis considered this
independent in association with inflammation-induced
atherosclerosis. The attenuation of atherosclerotic plaque
inflammation may be associated with increased HDL levels
as previous findings reported increased HDL cholesterol
levels after statin administration, but decreased plaque
inflammation in dyslipidemic patients (47). HDL cholesterol
promotes antioxidant, anti-inflammatory events attenuating
atherosclerosis (31), and high level of HDL can reduce the
odds of T2DM patients developing microvascular retinopathy
and renal disease (48). In contrast, the AIM-HIGH clinical
trial result found no cardiovascular benefit in 34% of its
participants with T2DM despite a noticeable increase in HDL
cholesterol level (49). The observation that atherosclerotic
plaque inflammation–attenuating properties of pioglitazone
could be largely ascribed to its HDL-increasing property
rather than its hs-CRP-lowering property suggests a difference
in systemic and plaque inflammation, and that hs-CRP, a
marker for chronic systemic inflammation, may not reflect
plaque inflammation (31). Nevertheless, the study suggests
that pioglitazone could be a potent intervention in attenuating
inflammation-induced atherosclerosis.
The findings on salsalate treatment and the outcome
from combined treatment with simvastatin and fenofibrate
were insightful and beneficial. Barzilay et al. (27) in a 48-
week TINSAL-T2D study found that salsalate moderated
hyperglycemia and serum levels of AGEs which are involved
in diabetes-related vascular complications after 118 out of 207
total participants received 3.5 g/day of salsalate (27). A noticeable
significant change (p > 0.05) in WBC and furosine but not in
other glycation products for CRP and TNF in salsalate users was
reported (27). Although Barzilay et al. (27) stated that the reasons
for not detecting a change in serum-protein-bound AGE levels
were not exactly known, the fact that AGE could have multiple
pathways, that metformin was taken by most participants, and
that the salsalate-treated participants with hypoglycemic events
were receiving reduced antihyperglycemic medications were
suggested as a possible explanation. Barzilay et al. (27) found
that salsalate had no effect on late AGEs but reduced early AGEs
and had a significant lowering effect on HbA1c; however, there
was an increase in serum pentosidine (an AGE) indicating the
possibility of induced oxidative stress, while changes in markers
of inflammation or renal factors were independent of changes in
pentosidine and glycation factors.
Interestingly, Krysiak et al. (29) in a separate study found
a significant decrease (p = 0.001) in all of TNF, IL-1, IL-
2, IL-6, MCP-1, and CRP inflammatory activities after
a combined treatment with simvastatin and fenofibrate,
but a weak correlation (r = 0.20) with single fenofibrate
administration. The study, which involved 196 T2DM
participants with mixed dyslipidemia, reported that the
medications exerted a similar but more efficacious effect
on systemic inflammation after combined administration (29).
However, single administration of simvastatin reducedmonocyte
release of pro-inflammatory cytokines such as TNF-α, IL-1β,
IL-6, and monocyte chemoattractant protein-1 (MCP-1); and
lymphocyte release of IL-2, interferon-γ, and TNF-α; including
a decrease in plasma CRP levels, while single administration of
fenofibrate had anti-inflammatory effects that correlated with
improved insulin sensitivity and downregulation of lymphocytes
rather than monocytes (29). Lymphocytes and monocytic cells
are present in atherosclerotic plaques and are very well associated
with the progression of atherosclerosis (50–52).
Assessment of the RCTs using medication as an intervention
showed that none of the four studies were multi-country and
majority of the selected participants were males; for example,
the RCT by Alkhalaf et al. (23) was conducted in an outpatient
clinic in the Netherlands and all participants were males which
limits the conclusion for females. The representation of gender
was skewed toward the male in the other studies; for example,
selected participants in the study by Krysiak et al. (29) had 108
males and 82 females. Also, Barzilay et al. (27) had 130 male and
97 female participants, while there were 39 males and 13 females
in the study by Mizoguchi et al. (31). All participants had T2DM;
however, participants in the study by Alkhalaf et al. (23) also had
UAE, while those in the RCT conducted by Krysiak et al. (29)
had untreated T2DM. These additional disorders may represent
confounding factors which may not have been accounted for by
the RCTs.
DISCUSSION
Diabetic angiopathies can be induced by low-grade
inflammation, AGEs, and endothelial dysfunction which
are considered intermediate pathways (23). TNF-α, IL-1β, IL-6,
MCP-1, IL-2, and interferon-γ are some of the monocyte- and
lymphocyte-derived pro-inflammatory cytokines (29); these
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cytokines as well as CRP are markers of chronic low-grade
systemic inflammation and prognostic indicators of vascular
complications and increased cardiovascular risk (29). The risk
for vascular complications and the extent of insulin resistance
have been linked with changes in the levels of these inflammatory
markers (53–55). Inflammation just like hyperglycemia, is
an integral process leading to atherosclerosis and increased
risk of atherosclerotic cardiovascular disease (31). However,
there is little evidence to suggest that a particular oral anti-
diabetic medication is the preferred intervention to ameliorate
inflammation-induced atherosclerosis or angiopathies (31).
Drugs such as pioglitazone, simvastatin, and fenofibrate, and
non-acetylated salicylate such as salsalate but not benfotiamine
suggested benefits in moderating vascular complications
(23, 27, 29, 31).
Benfotiamine had been previously suggested as a therapy for
diabetic nephropathy and other related complications through its
activation of transketolase for the inhibition of AGE precursors,
low-grade inflammation, and endothelial dysfunction in an
experiment using animals with diabetes (56, 57). Transketolase,
an enzyme involved in the breakdown of glucose, plays a role
in inhibiting vascular complications (58, 59), and although
Alkhalaf et al. (23) reported a significant increase in transketolase
activity (a co-factor of thiamine), no significant findings from
benfotiamine administration across the two study groups were
observed, suggesting that further long-term studies are needed to
understand the pathway and mechanisms of its action in humans
(56). The study by Alkhalaf et al. (23) was one of the few papers
that reported findings onmeasures of inflammatorymarkers after
benfotiamine administration.
Nonetheless, the TINSAL-T2D study found that salsalate
treatment did not overly change most AGE levels (27). However,
pioglitazone was found to ameliorate inflammation-induced
atherosclerosis in T2DM. Mizoguchi et al. (31) evaluating the
effect of 0.5–4.0mg glimepiride and 15–30mg pioglitazone
intervention on atherosclerotic plaque inflammation after
4 months, found that both interventions decreased HbA1c,
but only pioglitazone ameliorated inflammation-induced
atherosclerosis. This result agreed with the PERISCOPE
and CHICAGO studies that showed that when compared
with glimepiride, pioglitazone prevented the continuous
development of carotid or coronary atherosclerosis after
18 months of treatment (60, 61), providing evidence for
pioglitazone as a protective risk factor for diabetes-related
angiopathies. Furthermore, the use of simvastatin, a drug with
anti-inflammatory properties (29, 62, 63), and fenofibrate
was found to be a clinically relevant medication in the
treatment of low-grade inflammation for the prevention of
atherosclerosis (29).
Nevertheless, there are contrasting findings on fenofibrate
intervention in other studies. For example, the FIELD and
BIP trial studies on lowering events in diabetes found that
fibrate significantly decreased cardiovascular risk by only 19 and
17%, respectively; although there was a decrease in mortality
and nonfatal heart attack, the result was not significant (64).
In addition, the Action to Control Cardiovascular Risk in
Diabetes Lipid trial (ACCORD) after a 10-year study reported
decreased cerebrovascular risks in middle-aged and older
T2DM patients using simvastatin intervention alone or in
combination with fenofibrate (65). The difference between the
findings by Krysiak et al. (29) and the ACCORD trial was on
the superior potency of the combination of simvastatin and
fenofibrate compared with monotherapy. The ACCORD trial
highlighted the potency of simvastatin as well as in combination
with fenofibrate, while Krysiak et al. (29) reported that both
combined and monotherapy administration of simvastatin and
fenofibrate equally affected monocyte cytokine release, but only
the combined medication decreased lymphocyte cytokine release
and improved lipid profile. These differences could be associated
with the characteristics of the participants as Krysiak et al. (29)
included lifestyle modification and metformin in the study of
a small number of newly diagnosed patients with T2DM who
also had dyslipidemia, and administered the combined therapy
at reduced dosage for a shorter period, unlike the ACCORD trial
that was a 10-year study.
The role of systemic inflammation in T2DM-related vascular
complications have been linked with low levels of soluble
receptor for AGEs (24) and chronic inflammation which is
correlated with increasing risk for cardiovascular events (28).
Soluble RAGE was suggested to ameliorate the adverse and
inflammatory action of RAGE, and patients with T2DM have
been reported to have low levels of circulating soluble RAGE (66,
67). The circulating soluble RAGE has an indirect relationship
with insulin resistance, HbA1c, and CRP, making it a marker
and predictor for inflammation and cardiovascular events (68,
69). The report on lower systemic inflammation due to the
induction of soluble RAGE in patients with T2DM by Choi
et al. (24) is consistent with other studies by Arikawa et al. (70),
Nadar and Lundberg (71), and Riesco et al. (72) all of whom
reported significant decrease in CRP and IL-6 levels after 4–
6 months of regular exercise. The precise fundamental process
responsible for generating soluble RAGE via regular exercise
remains unclear (24).
Accordingly, pro-inflammatory markers such as IL-18 are
elevated in diabetes and strongly considered as an independent
predictor of adverse cardiovascular events (73, 74). The
alterations in IL-18 were positively linked with changes in
insulin resistance in one of the selected studies (28), and other
studies have reported changes in IL-18 levels influenced by
lifestyle modification such as exercise (28, 75). The process
in which exercise lowers IL-18 concentration is probably
by modifying insulin signaling or downregulating cytokine
production decreasing inflammatory cell infiltration of adipose
tissues (76); however, determining the association of the
cause and effect still remains unclear (28). In contrast, anti-
inflammatory serum levels of IL-10 secreted by T cells of Th2
subtype, macrophages, and monocytes in humans have been
shown to cancel out the risk of cardiac events (33).
Inflammation independently induces the risk for hypertension
(25, 77, 78). Modern diets are said to be replete with AGEs which
are generated during food processing and have been implicated
in the pathogenesis of diabetes-related disorders due to their
ability to activate chronic low-grade inflammation and insulin
resistance (79). The speed at which AGEs increase in amount in
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the body differs among people and is dependent on lifestyle such
as cigarette smoking, consumption of AGE-rich diet, age, and
metabolic health of an individual (79). The consumption of AGE-
rich diet (e.g., fried meats, glycated proteins, toasted wheat flakes,
etc.) leads to the proliferation of pathogenic colonic bacteria;
therefore, eating healthy diets low in AGE may reduce AGE
accumulation from exogenous sources. Yet, the difficulty is in
resisting and overcoming the temptation to consume those meals
as AGE-rich diets have enhanced aroma, flavor, and color (80).
One solution has been the supplementation with prebiotic fibers
which improve optimal gut microbial balance to inhibit AGE in
people at risk of T2DM (79). Prebiotic fibers such as inulin and
raspberries could reduce the glycemic index of a diet, slow the
absorption of intestinal nutrient, and delay gastric emptying (79).
Dietary interventions geared at preventing the progression
of inflammatory activities are necessary to attenuate diabetes-
related angiopathies. Hesperidin, ginger, and dietary raspberry
supplementation from the selected studies were suggested
as dietary supplements that could ameliorate the effect of
inflammation and AGEs (25, 26, 30). Hesperidin inhibits
the production of inflammatory cytokines that increase
arterial stiffness and peripheral vascular resistance which are
indications for hypertension and vascular complications (24).
Raspberries are prebiotic fibers whose products may lower the
absorption of exogenous AGE in the gut and inhibit circulating
proinflammatory cytokines; they can also induce changes that
enhance gut barrier functioning by elevating the production of
glucagon-like peptide 2 (GLP-2) which promotes an increase in
crypt cells (79, 81, 82). Food supplements like ginger have been
reported to have anti-inflammatory and anti-oxidant properties
(30) which lowers ADMA, which when elevated decreases NO
production leading to decreased blood supply to peripheral
tissues (30).
An increase in ADMA promotes the activation of nuclear
factor kappa B (NF-κB) transcription factor which is associated
with increased ICAM-1 and proinflammatory cytokine
production (30). ICAM-1 is a protein expressed through
NF-κB pathway in endothelial cells and leukocytes (30). ADMA
makes the NF-κB pathway active, leading to increased ICAM-
1 (83). ADMA and ICAM-1 play a role in diabetes-related
cardiovascular complications and insulin resistance level as
they are involved in pathway association with oxidative stress,
NO inhibition, increased blood pressure, and inflammation
(84–87). During inflammatory conditions, leukocytes produce
and attach ICAM-1 protein to endothelial cells promoting
macrophage production of foam cells (88). Therefore, inhibition
of NF-κB transcription factor, ADMA, and ICAM-1 could
prevent cardiovascular complications in T2DM (30).
Taken all together, there was limited information on
participant compliance during the interventions. Also, not all
studies included information on gender and disclosed the current
medication in the baseline characteristics of the participants
at the beginning and end of the study, especially because the
participants were known T2DM patients. Most studies had more
male participants and were not multi-country, implying lack of
diversity in racial origin and ethnicity which could potentially
limit the representation of the conclusions. It is important to note
that the selected studies looked at interventions on inflammatory
activities in people with diabetes. Moreover, the data selection
was done by a single reviewer but verified by another reviewer
for consistency. The small sample size of participants and limited
RCTs on inflammatory activities in T2DM-related comorbidities
is a limitation. However, the study contributes to medical
knowledge and education for carers and people with diabetes-
related angiopathies by reviewing information on how intake
of healthy dietary supplements, aerobic exercise, and anti-
inflammatory medications can improve protection from future
risk by highlighting beneficial interventions that may lower the
potential for negative outcomes.
CONCLUSION
Elevated inflammatory activities and its association pathways
such as endothelial dysfunction and AGEs have been reported
in diabetes-related vascular disorders. TNF-α and IL-6
were the most common proinflammatory cytokines from
the selected studies; together with CRP, their alterations
represent an important biomarker for accessing inflammatory
activities in diabetic angiopathies. The activities of IL-10,
an anti-inflammatory cytokine, is helpful in accessing
reduced risk for induced inflammation in diabetes-related
angiopathies. Regular aerobic exercise, medications that decrease
proinflammatory activities, as well as diet rich in prebiotic
fibers and those possessing anti-inflammatory properties were
suggested as a means of attenuating the risk of increased
proinflammatory events.
A summary of knowledge from the findings suggested that
salsalate treatment could reduce inflammatory activity but may
not change AGE levels which is linked to oxidative stress
because markers of serum inflammation only indirectly reflect
oxidative stress. The single administration of simvastatin was
found to downregulate monocytic and lymphocytic release of
proinflammatory markers, whereas fenofibrate only reduced
markers of lymphocytic inflammation. The administration of
both drugs were suggested to halt the progression of diabetes-
related atherosclerosis because lymphocytes and monocytic cells
are present in atherosclerotic plaques. Similarly, pioglitazone was
found to prevent the continuous progression of inflammation-
induced atherosclerosis by increasing HDL and lowering hs-
CRP levels, indicating its involvement in reducing systemic and
plaque inflammation.
Finally, while it is known that changes in metabolic status and
cytokines could increasingly alter insulin action, and that exercise
may lower cellular apoptosis and atherosclerotic plaque, not
much of this has been studied with regards to people with T2DM
and existing angiopathies or on the effectiveness of various
food supplements. In this study, aerobic exercise was shown to
reduce risk factors associated with vascular and cardiometabolic
risk by increasing soluble RAGE which interacts with AGE,
a known promoter of atherosclerosis in diabetes condition.
Indeed, the review showed that regular exercise increases anti-
inflammatory activities and reduces proinflammatory events and
mediators of oxidative stress such as AGE which is high in
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AGE-rich diets. Prebiotic fibers such as raspberries lower the
absorption of AGEs in the gut, while ginger and hesperidin lower
inflammatory activities that promote cardiovascular and vascular
complications by suppressing ADMA, regulating ICAM-1, and
stimulating DDAH and NO production. Thus, medication and
healthy dietary supplements with anti-inflammatory properties,
along with regular exercise, may result in beneficial outcome for
diabetes patients.
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